World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

Todd Franklin Watanabe net worth and biography

Todd Watanabe Biography and Net Worth

CEO of Arcutis Biotherapeutics

Todd Franklin Watanabe serves as President, Chief Executive Officer, Director of the Company. Prior to joining Arcutis Biotherapeutics, he served as co-founder and Chief Operating Officer of Kanan Therapeutics, Inc., a cardiovascular drug development company from December 2015 to February 2018, and before that, he served as Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals Inc. from October 2013 to November 2015. Mr. Watanabe was an executive at Amgen, Inc. from 2005 to 2013, where he was involved in the development of Repatha for hyperlipidemia and Aimovig for migraine, and worked on the U.S. marketing of Enbrel in both dermatology and rheumatology. Previously, he was an executive with Eli Lilly and company, and an official in the U.S. Government. He was also a commissioned officer in the U.S. Navy Reserves for 25 years. Mr. Watanabe received his M.A. in National Security Studies, and his B.A. in International Relations, both from Georgetown University. Watanabe is qualified to serve on our board of directors because of his experience

What is Todd Franklin Watanabe's net worth?: The estimated net worth of Todd Franklin Watanabe is at least $3.15 million as of March 6th, 2023. Mr. Watanabe owns 366,657 shares of Arcutis Biotherapeutics stock worth more than $3,149,584 as of April 25th. This net worth evaluation does not reflect any other investments that Mr. Watanabe may own. Additionally, Mr. Watanabe receives an annual salary of $1,010,000.00 as CEO at Arcutis Biotherapeutics. Learn More about Todd Franklin Watanabe's net worth.
How old is Todd Franklin Watanabe?: Mr. Watanabe is currently 56 years old. There are 5 older executives and no younger executives at Arcutis Biotherapeutics. Learn More on Todd Franklin Watanabe's age.
What is Todd Franklin Watanabe's salary?: As the CEO of Arcutis Biotherapeutics, Inc., Mr. Watanabe earns $1,010,000.00 per year. Learn More on Todd Franklin Watanabe's salary.
How do I contact Todd Franklin Watanabe?: The corporate mailing address for Mr. Watanabe and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Todd Franklin Watanabe's contact information.
Has Todd Franklin Watanabe been buying or selling shares of Arcutis Biotherapeutics?: Todd Franklin Watanabe has not been actively trading shares of Arcutis Biotherapeutics during the last quarter. Most recently, Todd Franklin Watanabe sold 2,435 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $15.26, for a transaction totalling $37,158.10. Following the completion of the sale, the insider now directly owns 366,657 shares of the company's stock, valued at $5,595,185.82. Learn More on Todd Franklin Watanabe's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 1 times. They purchased a total of 80,000 shares worth more than $200,000.00. During the last year, insiders at the sold shares 5 times. They sold a total of 10,370 shares worth more than $75,737.90. The most recent insider tranaction occured on March, 4th when insider Masaru Matsuda sold 3,760 shares worth more than $41,811.20. Insiders at Arcutis Biotherapeutics own 20.7% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 3/4/2024.

Todd Franklin Watanabe Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2023	Sell	2,435	$15.26	$37,158.10	366,657
3/2/2023	Sell	5,472	$15.83	$86,621.76	369,092
2/28/2023	Sell	2,343	$16.17	$37,886.31	374,564
2/13/2023	Sell	483	$17.00	$8,211.00	377,424
12/7/2022	Sell	1,000	$17.06	$17,060.00	378,907
11/7/2022	Sell	1,000	$18.00	$18,000.00	379,907
10/7/2022	Sell	1,000	$19.51	$19,510.00	380,907
9/7/2022	Sell	1,000	$21.51	$21,510.00	381,907
7/8/2022	Sell	13,500	$25.37	$342,495.00	651,871
7/6/2022	Sell	1,000	$22.07	$22,070.00	658,284
5/5/2022	Sell	1,000	$21.76	$21,760.00	658,667
4/5/2022	Sell	1,000	$21.43	$21,430.00	659,667
3/9/2022	Sell	300	$17.00	$5,100.00
3/7/2022	Sell	770	$17.05	$13,128.50
3/4/2022	Sell	2,489	$16.86	$41,964.54
2/9/2022	Sell	1,000	$17.00	$17,000.00
1/5/2022	Sell	1,000	$21.59	$21,590.00
12/8/2021	Sell	1,000	$17.00	$17,000.00
11/5/2021	Sell	1,000	$21.50	$21,500.00
10/5/2021	Sell	2,500	$24.92	$62,300.00
9/7/2021	Sell	1,000	$21.14	$21,140.00
8/5/2021	Sell	1,000	$20.81	$20,810.00
7/6/2021	Sell	1,750	$26.58	$46,515.00
6/7/2021	Sell	1,750	$26.35	$46,112.50
5/7/2021	Sell	750	$35.00	$26,250.00
5/5/2021	Sell	1,750	$34.00	$59,500.00
4/5/2021	Sell	1,750	$29.93	$52,377.50
3/5/2021	Sell	1,750	$30.55	$53,462.50
9/29/2020	Sell	3,000	$30.00	$90,000.00	569,928

Todd Franklin Watanabe Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $8.59

$8.21

$8.71

50 Day Range

MA: $10.17

$7.97

$12.53

2 Week Range

Now: $8.59

$1.76

$15.21

Volume

2,251,945 shs

Average Volume

4,627,841 shs

Market Capitalization

$831.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Mysterious Gold Leverage Just Announced

From Stansberry Research | Ad

Find out what it is and see how you can get in with just a few dollars.

Todd Watanabe Biography and Net Worth

What is Todd Franklin Watanabe's net worth?

How old is Todd Franklin Watanabe?

What is Todd Franklin Watanabe's salary?

How do I contact Todd Franklin Watanabe?

Has Todd Franklin Watanabe been buying or selling shares of Arcutis Biotherapeutics?

Who are Arcutis Biotherapeutics' active insiders?

Are insiders buying or selling shares of Arcutis Biotherapeutics?